<!DOCTYPE html><html><head><title>Heart failure in adults: percentage of patients with heart failure diagnosis and LVSD who at the last clinic visit met the following (if eligible): prescribed or were on ACEI/ARB, prescribed or were on beta-blocker therapy, and a non-smoker.</title><link rel="stylesheet" type="text/css" href="style.css"></head><body><div class='section'>
<h2>General
</h2>
<div class='field field_text'>
<h3>
Title
</h3>
<div class='FieldValue'>
<div class="content_title">Heart failure in adults: percentage of patients with heart failure diagnosis and LVSD who at the last clinic visit met the following (if eligible): prescribed or were on ACEI/ARB, prescribed or were on beta-blocker therapy, and a non-smoker.</div>
</div>

</div>
<div class='field field_citation'>
<h3>
Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>Pinkerman C, Sander P, Breeding JE, Brink D, Curtis R, Hayes R, Ojha A, Pandita D, Raikar S, Setterlund L, Sule O, Turner A. Heart failure in adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2013 Jul. 94 p.  [190 references]</td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>Measure Domain
</h2>
<div class='field field_picklist-one'>
<h3>
Primary Measure Domain
</h3>
<div class='FieldValue'>
Clinical Quality Measures: Process
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Secondary Measure Domain
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>

</div>
<div class='section'>
<h2>Brief Abstract
</h2>
<div class='field field_text'>
<h3>
Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This measure is used to assess the percentage of patients age 18 years and older with heart failure diagnosis and left ventricular systolic dysfunction (LVSD) who at the last clinic visit met the following (if eligible): prescribed or were on angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB), prescribed or were on beta-blocker therapy, and a non-smoker. </p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Rationale
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The priority aim addressed by this measure is to increase the rate of heart failure patients age 18 years and older who receive optimum evidence-based pharmacologic treatment.</p>
<p>Heart failure is a major health problem in the United States (U.S.), and the incidence of the disease is increasing. The overall estimated 2004 prevalence of heart failure in adults age 20 and older in the U.S. was 5.2 million, with it being equally distributed among men and women.</p>
<p>The cornerstone of treatment of systolic dysfunction is the use of beta-blockers and angiotensin-converting enzyme (ACE) inhibitors. Certain beta-blocking medications have been shown to improve clinical symptoms and ventricular function in patients with systolic dysfunction. Beta-blockers decrease hospitalizations and mortality, and have objective beneficial effect on measures of exercise duration.</p>
<p>ACE inhibitors prolong life in patients with heart failure symptoms and ejection fraction (EF) less than 35% and reduce symptom development in asymptomatic patients with EF less than 35%. There is also a mortality benefit in the use of ACE inhibitors in patients with recent myocardial infarction and asymptomatic EF less than 40%. ACE inhibitors slow disease progression, improve exercise capacity and decrease hospitalizations and mortality. Angiotensin receptor blockers (ARBs) are recommended for patients intolerant of ACE inhibitors.</p></div>
</div>

</div>
<div class='field field_citation'>
<h3>
Evidence for Rationale
</h3>
<div class='FieldValue'>
<table><tr><td>Andersson B, Hamm C, Persson S, Wikstrom G, Sinagra G, Hjalmarson A, Waagstein F. Improved exercise hemodynamic status in dilated cardiomyopathy after beta-adrenergic blockade treatment. J Am Coll Cardiol. 1994 May;23(6):1397-404. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8176099" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996 Dec 1;94(11):2807-16. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8941106" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group. JAMA. 1988 Jan 22-29;259(4):539-44. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=2447297" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987 Jun 4;316(23):1429-35. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=2883575" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med. 1992 Sep 3;327(10):685-91. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1463530" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999 Jun 12;353(9169):2001-7. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10376614" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, American College of Cardiology Foundation, American Heart Association. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults [trunc]. J Am Coll Cardiol. 2009 Apr 14;53(15):e1-e90. [810 references] <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=19358937" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>National Health and Nutrition Examination Survey 1999 to 2004 [NHANES] Data 1999-2004. [internet]. Hyattsville (MD): National Center for Health Statistics; </td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996 May 23;334(21):1349-55. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8614419" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001 May 31;344(22):1651-8. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11386263" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002 Oct 22;106(17):2194-9. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12390947" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999 Dec 7;100(23):2312-8. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10587334" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669-77. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1386652" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Pinkerman C, Sander P, Breeding JE, Brink D, Curtis R, Hayes R, Ojha A, Pandita D, Raikar S, Setterlund L, Sule O, Turner A. Heart failure in adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2013 Jul. 94 p.  [190 references]</td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003 Jul 5;362(9377):7-13. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12853193" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004 Jul 21;292(3):344-50. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15265849" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991 Aug 1;325(5):293-302. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=2057034" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999 Jan 2;353(9146):9-13. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10023943" target="_blank">PubMed</a></td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Primary Health Components
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Heart failure; left ventricular systolic dysfunction (LVSD); angiotensin-converting enzyme inhibitor (ACEI); angiotensin receptor blocker (ARB); beta-blocker; smoking status</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Denominator Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Number of patients age 18 years and older with a diagnosis of heart failure and left ventricular systolic dysfunction (LVSD) (see the related "Denominator Inclusions/Exclusions" field)</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Numerator Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Number of patients 18 years and older with a diagnosis of heart failure and left ventricular systolic dysfunction (LVSD) who were prescribed or were taking angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB), beta-blocker therapy and a non-smoker</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Evidence Supporting the Measure
</h2>
<div class='field field_picklist-choice'>
<h3>
Type of Evidence Supporting the Criterion of Quality for the Measure
</h3>
<div class='FieldValue'>
A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence
</div>

</div>
<div class='field field_text'>
<h3>
Additional Information Supporting Need for the Measure
</h3>
<div class='FieldValue'>
<ul style="list-style-type: disc;">
    <li>In age 20 to 39, the incidence of heart failure is 0.3% of the population in men and 0.2% of the population in women. In the ages 40s and 50s, the incidence is 2% in men and 1.5% in women. In the 60 to 79 age group, the incidence is 7.2% in men and 5.2% in women. However, once reaching age 80, the incidence of heart failure is higher in women, with 11.6% of men and 12.4% of women. </li>
    <li>Seventy-five percent of heart failure cases have antecedent hypertension in that the lifetime risk for heart failure doubles for people with blood pressure greater than 160/90 versus those with blood pressure less than 140/90. A community-based cohort study conducted in Olmsted County, Minnesota, showed that the incidence of heart failure (International Classification of Diseases, Ninth Revision [ICD9]-428) has not declined during the past two decades, but survival after onset has increased overall, with less improvement among women and elderly persons.</li>
</ul>
</div>

</div>
<div class='field field_citation'>
<h3>
Evidence for Additional Information Supporting Need for the Measure
</h3>
<div class='FieldValue'>
<table><tr><td>National Health and Nutrition Examination Survey 1999 to 2004 [NHANES] Data 1999-2004. [internet]. Hyattsville (MD): National Center for Health Statistics; </td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Pinkerman C, Sander P, Breeding JE, Brink D, Curtis R, Hayes R, Ojha A, Pandita D, Raikar S, Setterlund L, Sule O, Turner A. Heart failure in adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2013 Jul. 94 p.  [190 references]</td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004 Jul 21;292(3):344-50. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15265849" target="_blank">PubMed</a></td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Extent of Measure Testing
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>
<div class='field field_xref'>
<h3>
National Guideline Clearinghouse Link
</h3>
<div class='FieldValue'>
<a href="http://www.guideline.gov/content.aspx?id=47030" target="_blank">Heart failure in adults.</a>
</div>

</div>

</div>
<div class='section'>
<h2>State of Use of the Measure
</h2>
<div class='field field_picklist-one'>
<h3>
State of Use
</h3>
<div class='FieldValue'>
Current routine use
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Current Use
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>

</div>
<div class='section'>
<h2>Application of the Measure in its Current Use
</h2>
<div class='field field_picklist-choice'>
<h3>
Measurement Setting
</h3>
<div class='FieldValue'>
Ambulatory/Office-based Care
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Professionals Involved in Delivery of Health Services
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Least Aggregated Level of Services Delivery Addressed
</h3>
<div class='FieldValue'>
Clinical Practice or Public Health Sites
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Statement of Acceptable Minimum Sample Size
</h3>
<div class='FieldValue'>
Unspecified
</div>

</div>
<div class='field field_text'>
<h3>
Target Population Age
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Age greater than or equal to 18 years</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Target Population Gender
</h3>
<div class='FieldValue'>
Either male or female
</div>

</div>

</div>
<div class='section'>
<h2>National Strategy for Quality Improvement in Health Care
</h2>
<div class='field field_text'>
<h3>
National Quality Strategy Aim
</h3>
<div class='FieldValue'>
<ul><li>Better Care</li></ul>
</div>

</div>
<div class='field field_text'>
<h3>
National Quality Strategy Priority
</h3>
<div class='FieldValue'>
<ul><li>Prevention and Treatment of Leading Causes of Mortality</li></ul>
</div>

</div>

</div>
<div class='section'>
<h2>Institute of Medicine (IOM) National Health Care Quality Report Categories
</h2>
<div class='field field_picklist-choice'>
<h3>
IOM Care Need
</h3>
<div class='FieldValue'>
Living with Illness
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
IOM Domain
</h3>
<div class='FieldValue'>
Effectiveness
</div>

</div>

</div>
<div class='section'>
<h2>Data Collection for the Measure
</h2>
<div class='field field_text'>
<h3>
Case Finding Period
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The time frame pertaining to data collection is quarterly.</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Denominator Sampling Frame
</h3>
<div class='FieldValue'>
Patients associated with provider
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Denominator (Index) Event or Characteristic
</h3>
<div class='FieldValue'>
Clinical Condition
</div>
<div class='FieldValue'>
Encounter
</div>
<div class='FieldValue'>
Patient/Individual (Consumer) Characteristic
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Denominator Time Window
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_text'>
<h3>
Denominator Inclusions/Exclusions
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Inclusions</strong><br />
Number of patients age 18 years and older with a diagnosis of heart failure* and left ventricular systolic dysfunction (LVSD)**</p>
<p class="Note"><strong>Data Collection</strong>: Query electronic medical records (EMR) for clinic visits within the last 12 months for patients age 18 years and older with heart failure diagnosis and LVSD. Determine if patients meet any exclusion criteria. For patients who meet exclusion criteria, exclude them from the analysis.</p>
<p class="Note">*International Classification of Diseases, Ninth Revision (ICD-9) codes: 428.0, 428.1, 428.20, 428.21, 428.22, 428.23, 428.40, 428.41, 428.42, 428.43, 428.9. (Refer to the table "Descriptions of ICD-9 Codes" in the original measure documentation for code descriptions.)</p>
<p class="Note">**LVSD is defined quantitatively as left ventricular ejection fraction less than 40%, and qualitatively as moderately or severely depressed left ventricular systolic function.</p>
<p><strong>Exclusions</strong></p>
<ul style="list-style-type: disc;">
    <li>Patients less than 18 years of age </li>
    <li>Patients with potential contraindications or other reasons for the provider to not prescribe an angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) and/or beta-blocker (refer to the original measure documentation for a complete list) </li>
    <li>Patients transferred to another care system </li>
    <li>Patients with devices </li>
    <li>Deceased patients </li>
</ul></div>
</div>

</div>
<div class='field field_picklist-choice-4'>
<h3>
Exclusions/Exceptions
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_text'>
<h3>
Numerator Inclusions/Exclusions
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Inclusions</strong><br />
Number of patients 18 years and older with a diagnosis of heart failure and left ventricular systolic dysfunction (LVSD) who were prescribed or were taking angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB), beta-blocker therapy and a non-smoker</p>
<p><strong>Exclusions</strong><br />
Unspecified</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Numerator Search Strategy
</h3>
<div class='FieldValue'>
Encounter
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Data Source
</h3>
<div class='FieldValue'>
Administrative clinical data
</div>
<div class='FieldValue'>
Electronic health/medical record
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Type of Health State
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>
<div class='field field_text'>
<h3>
Instruments Used and/or Associated with the Measure
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Computation of the Measure
</h2>
<div class='field field_picklist-one'>
<h3>
Measure Specifies Disaggregation
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Scoring
</h3>
<div class='FieldValue'>
Rate/Proportion
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Interpretation of Score
</h3>
<div class='FieldValue'>
Desired value is a higher score
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Allowance for Patient or Population Factors
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Standard of Comparison
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>

</div>
<div class='section'>
<h2>Identifying Information
</h2>
<div class='field field_text'>
<h3>
Original Title
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Percentage of patients with heart failure diagnosis and LVSD who at the last clinic visit met the following (if eligible): prescribed or were on ACEI/ARB, prescribed or were on beta-blocker therapy, and a non-smoker. </p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Collection Name
</h3>
<div class='FieldValue'>
Heart Failure in Adults
</div>

</div>
<div class='field field_orglist'>
<h3>
Submitter
</h3>
<div class='FieldValue'>
Institute for Clinical Systems Improvement - Nonprofit Organization
</div>

</div>
<div class='field field_orglist-p'>
<h3>
Developer
</h3>
<div class='FieldValue'>
Institute for Clinical Systems Improvement - Nonprofit Organization
</div>

</div>
<div class='field field_text'>
<h3>
Funding Source(s)
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The Institute for Clinical Systems Improvement's (ICSI's) work is funded by the annual dues of the member medical groups and five sponsoring health plans in Minnesota and Wisconsin.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Composition of the Group that Developed the Measure
</h3>
<div class='FieldValue'>
<div class="content_para"><p><em>Work Group Members</em>: Charles Pinkerman, MD (<em>Work Group Leader</em>) (Park Nicollet Health Services) (Cardiology); Paul Sander, MD (<em>Work Group Leader</em>) (North Memorial Health Care) (Cardiology); Joshua E. Breeding, PharmD, BCPS (Fairview Health Services) (Pharmacist); Shama Raikar, MD (HealthPartners Medical Group and Regions Hospital) (Internal Medicine); Oghomwen Sule, MD (Howard Young Medical Center) (Internal Medicine); Ashok Ojha, MD (Hutchinson Medical Center) (Internal Medicine); Rochelle Curtis, PA (Park Nicollet Health Services) (Cardiology); Deepti Pandita, MD (Park Nicollet Health Services) (Internal Medicine); Angela Turner, PA-C (Park Nicollet Health Services) (Cardiology); Darin Brink, MD (University of Minnesota Physicians) (Family Medicine); Rochelle Hayes, BS (Institute for Clinical Systems Improvement) (Systems Improvement Coordinator); Linda Setterlund, MA, CPHQ (Institute for Clinical Systems Improvement) (Clinical Systems Improvement Facilitator)</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Financial Disclosures/Other Potential Conflicts of Interest
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The Institute for Clinical Systems Improvement (ICSI) has long had a policy of transparency in declaring potential conflicting and competing interests of all individuals who participate in the development, revision and approval of ICSI guidelines and protocols. </p>
<p>In 2010, the ICSI Conflict of Interest Review Committee was established by the Board of Directors to review all disclosures and make recommendations to the board when steps should be taken to mitigate potential conflicts of interest, including recommendations regarding removal of work group members. This committee has adopted the Institute of Medicine Conflict of Interest standards as outlined in the report Clinical Practice Guidelines We Can Trust (2011). </p>
<p>Where there are work group members with identified potential conflicts, these are disclosed and discussed at the initial work group meeting. These members are expected to recuse themselves from related discussions or authorship of related recommendations, as directed by the Conflict of Interest committee or requested by the work group.</p>
<p>The complete ICSI policy regarding Conflicts of Interest is available at the <a href="https://www.icsi.org/_asset/fwsfmi/coi_policyletter.pdf" title="ICSI Web site">ICSI Web site</a>.</p>
<p><strong>Disclosure of Potential Conflicts of Interest</strong></p>
<p><strong>Joshua E. Breeding, PharmD, BCPS (Work Group Member)</strong> <br />
Pharmacy, Fairview Health Services <br />
National, Regional, Local Committee Affiliations: None <br />
Guideline Related Activities: None <br />
Research Grants: None <br />
Financial/Non-Financial Conflicts of Interest: None </p>
<p><strong>Darin Brink, MD (Work Group Member) </strong><br />
Family Medicine, University of Minnesota Physicians <br />
National, Regional, Local Committee Affiliations: None <br />
Guideline Related Activities: Colorectal Cancer Screening Guideline Work Group <br />
Research Grants: None <br />
Financial/Non-Financial Conflicts of Interest: None </p>
<p><strong>Rochelle Curtis, PA (Work Group Member)</strong> <br />
Cardiology, Park Nicollet Health Services <br />
National, Regional, Local Committee Affiliations: None <br />
Guideline Related Activities: None <br />
Research Grants: None <br />
Financial/Non-Financial Conflicts of Interest: None </p>
<p><strong>Ashok Ojha, MD (Work Group Member) </strong><br />
Internal Medicine, Hutchinson Medical Center <br />
National, Regional, Local Committee Affiliations: Minneapolis Heart Institute <br />
Guideline Related Activities: None <br />
Research Grants: None <br />
Financial/Non-Financial Conflicts of Interest: None </p>
<p><strong>Deepti Pandita, MD (Work Group Member)</strong> <br />
Internal Medicine, Park Nicollet Health Services <br />
National, Regional, Local Committee Affiliations: None <br />
Guideline Related Activities: Breast Cancer Treatment Guideline Work Group <br />
Research Grants: None <br />
Financial/Non-Financial Conflicts of Interest: None </p>
<p><strong>Charles Pinkerman, MD (Work Group Leader) </strong><br />
Cardiology, Park Nicollet Health Services <br />
National, Regional, Local Committee Affiliations: None <br />
Guideline Related Activities: None <br />
Research Grants: None <br />
Financial/Non-Financial Conflicts of Interest: None </p>
<p><strong>Shama Raikar, MD (Work Group Member)</strong> <br />
Internal Medicine, HealthPartners Medical Group and Regions Hospital <br />
National, Regional, Local Committee Affiliations: None <br />
Guideline Related Activities: Chronic Obstructive Pulmonary Disease <br />
Research Grants: None <br />
Financial/Non-Financial Conflicts of Interest: None </p>
<p><strong>Paul Sander, MD (Work Group Leader)</strong> <br />
Cardiology, North Memorial Health Care <br />
National, Regional, Local Committee Affiliations: None <br />
Guideline Related Activities: None <br />
Research Grants: None <br />
Financial/Non-Financial Conflicts of Interest: None </p>
<p><strong>Oghomwen Sule, MD (Work Group Member) </strong><br />
Internal Medicine, Howard Young Medical Center <br />
National, Regional, Local Committee Affiliations: None <br />
Guideline Related Activities: Diagnosis and Initial Treatment of Stroke <br />
Research Grants: None <br />
Financial/Non-Financial Conflicts of Interest: None </p>
<p><strong>Angela Turner, PA-C (Work Group Member)</strong> <br />
Cardiology, Park Nicollet Health Services <br />
National, Regional, Local Committee Affiliations: None <br />
Guideline Related Activities: None <br />
Research Grants: None <br />
Financial/Non-Financial Conflicts of Interest: None</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Adaptation
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This measure was not adapted from another source.</p></div>
</div>

</div>
<div class='field field_date'>
<h3>
Date of Most Current Version in NQMC
</h3>
<div class='FieldValue'>
2013 Jul
</div>

</div>
<div class='field field_text'>
<h3>
Measure Maintenance
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Scientific documents are revised every 12 to 24 months as indicated by changes in clinical practice and literature.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Date of Next Anticipated Revision
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The next scheduled revision will occur within 24 months.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This is the current release of the measure.</p>
<p>This measure updates a previous version: Institute for Clinical Systems Improvement (ICSI). Heart failure in adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2011 Aug. 110 p. </p>
<p>The measure developer reaffirmed the currency of this measure in January 2016.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Availability
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Source available for purchase from the <a href="https://www.icsi.org/guidelines__more/purchase_guidelines/" title="ICSI Web site">Institute for Clinical Systems Improvement (ICSI) Web site</a>. Also available to ICSI members for free at the <a href="https://www.icsi.org/guidelines__more/member_access/" title="ICSI Web site">ICSI Web site</a> and to Minnesota health care organizations free by request at the <a href="https://www.icsi.org/guidelines__more/minnesota_nonmember_access/" title="ICSI Web site">ICSI Web site</a>. </p>
<p>For more information, contact ICSI at 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; Phone: 952-814-7060; Fax: 952-858-9675; Web site: <a href="http://www.icsi.org" title="ICSI Web site">www.icsi.org</a>; E-mail: <a href="mailto:icsi.info@icsi.org">icsi.info@icsi.org</a>.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
NQMC Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NQMC summary was completed by ECRI on November 29, 2006. </p>
<p>This NQMC summary was updated by ECRI Institute on December 16, 2007 and on July 1, 2010. </p>
<p>This NQMC summary was retrofitted into the new template on July 25, 2011. </p>
<p>This NQMC summary was updated by ECRI Institute on October 16, 2012 and again on October 14, 2013.</p>
<p>The information was reaffirmed by the measure developer on January 13, 2016.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Copyright Statement
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NQMC summary (abstracted Institute for Clinical Systems Improvement [ICSI] Measure) is based on the original measure, which is subject to the measure developer's copyright restrictions.</p>
<p>The abstracted ICSI Measures contained in this Web site may be downloaded by any individual or organization. If the abstracted ICSI Measures are downloaded by an individual, the individual may not distribute copies to third parties.</p>
<p>If the abstracted ICSI Measures are downloaded by an organization, copies may be distributed to the organization's employees but may not be distributed outside of the organization without the prior written consent of the Institute for Clinical Systems Improvement, Inc.</p>
<p>All other copyright rights in the abstracted ICSI Measures are reserved by the Institute for Clinical Systems Improvement, Inc. The Institute for Clinical Systems Improvement, Inc. assumes no liability for any adaptations or revisions or modifications made to the abstracts of the ICSI Measures.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Production
</h2>
<div class='field field_citation'>
<h3>
Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>Pinkerman C, Sander P, Breeding JE, Brink D, Curtis R, Hayes R, Ojha A, Pandita D, Raikar S, Setterlund L, Sule O, Turner A. Heart failure in adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2013 Jul. 94 p.  [190 references]</td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>Disclaimer
</h2>
<div class='field field_text'>
<h3>
NQMC Disclaimer
</h3>
<div class='FieldValue'>
<p>The National Quality Measures Clearinghouseâ„¢ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.</p> 
<p>All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.</p> 
<p>Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the <a href="/help-and-about/summaries/inclusion-criteria">NQMC Inclusion Criteria</a>.</p> 
<p>NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding measure content are directed to contact the measure developer.</p>
</div>

</div>

</div>
</body></html>